Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02 Article

Wen, Patrick Y, Chang, Susan M, Lamborn, Kathleen R et al. (2014). Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02 . NEURO-ONCOLOGY, 16(4), 567-578. 10.1093/neuonc/not247

Open Access

cited authors

  • Wen, Patrick Y; Chang, Susan M; Lamborn, Kathleen R; Kuhn, John G; Norden, Andrew D; Cloughesy, Timothy F; Robins, H Ian; Lieberman, Frank S; Gilbert, Mark R; Mehta, Minesh P; Drappatz, Jan; Groves, Morris D; Santagata, Sandro; Ligon, Azra H; Yung, WK Alfred; Wright, John J; Dancey, Janet; Aldape, Kenneth D; Prados, Michael D; Ligon, Keith L

sustainable development goals

authors

publication date

  • April 1, 2014

webpage

published in

keywords

  • ANTITUMOR-ACTIVITY
  • Clinical Neurology
  • EGFR KINASE INHIBITORS
  • GLIOBLASTOMA-MULTIFORME
  • GROWTH-FACTOR-RECEPTOR
  • II TRIAL
  • Life Sciences & Biomedicine
  • MAMMALIAN TARGET
  • MTOR INHIBITORS
  • Neurosciences & Neurology
  • Oncology
  • PLUS SIROLIMUS
  • PTEN-DEFICIENT
  • RAPAMYCIN INHIBITION
  • Science & Technology
  • anaplastic glioma
  • clinical trial
  • epidermal growth factor
  • erlotinib
  • glioblastoma
  • temsirolimus

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 567

end page

  • 578

volume

  • 16

issue

  • 4